Contact
searchSearch
HMP Global

June 2014 - FRMC

Specialty Pharmacies Helping to Evaluate Data and Use Technology to Reduce Costs and Improve Quality
06/19/2014
Tim Casey
Tampa—Within the next 5 years, specialty pharmaceuticals are expected to account for more than half of the overall drug spending in the United States. By 2016, 8 of the top 10 branded drugs will be specialty medications, while 53 specialty...
Tampa—Within the next 5 years, specialty pharmaceuticals are expected to account for more than half of the overall drug spending in the United States. By 2016, 8 of the top 10 branded drugs will be specialty medications, while 53 specialty...
Tampa—Within the next 5 years,...
06/19/2014
First Report Managed Care
Difficulties in Managing Hepatitis C
06/19/2014
Tim Casey
The FDA approved oral medications—sofosbuvir and simeprevir—to treat hepatitis C.
The FDA approved oral medications—sofosbuvir and simeprevir—to treat hepatitis C.
The FDA approved oral...
06/19/2014
First Report Managed Care
Injectable Antipsychotics for Medicaid Patients with Schizophrenia
06/19/2014
Kerri Fitzgerald
Tampa—Approximately 74% of patients with schizophrenia are nonadherent to oral antipsychotic medications. Even short treatment gaps with oral antipsychotics are associated with increased relapse risk, and 80% of patients with schizophrenia...
Tampa—Approximately 74% of patients with schizophrenia are nonadherent to oral antipsychotic medications. Even short treatment gaps with oral antipsychotics are associated with increased relapse risk, and 80% of patients with schizophrenia...
Tampa—Approximately 74% of...
06/19/2014
First Report Managed Care
Treatment Options for COPD
06/19/2014
Tim Casey
Orlando—In the United States, half of the 24 million people with chronic obstructive pulmonary disease (COPD) are undiagnosed. Still, a person dies from COPD every 4 minutes. The disease is the fourth leading cause of death and will be the...
Orlando—In the United States, half of the 24 million people with chronic obstructive pulmonary disease (COPD) are undiagnosed. Still, a person dies from COPD every 4 minutes. The disease is the fourth leading cause of death and will be the...
Orlando—In the United States,...
06/19/2014
First Report Managed Care
FDA-Approved Drugs and Lifestyle Changes for Obesity
06/19/2014
Tim Casey
According to the Centers for Disease Control and Prevention, 34.9% of adults in the United States are obese, while the estimated obesity-related costs are $147 billion per year.
According to the Centers for Disease Control and Prevention, 34.9% of adults in the United States are obese, while the estimated obesity-related costs are $147 billion per year.
According to the Centers for...
06/19/2014
First Report Managed Care
National Pain Strategy for Opioids and Other Medications
06/19/2014
Tim Casey
Orlando—A 2011 report from the Institute of Medicine (IOM) found that chronic pain affects 116 million people in the United States, more than the total affected by heart disease, cancer, and diabetes combined. The disease also costs the...
Orlando—A 2011 report from the Institute of Medicine (IOM) found that chronic pain affects 116 million people in the United States, more than the total affected by heart disease, cancer, and diabetes combined. The disease also costs the...
Orlando—A 2011 report from the...
06/19/2014
First Report Managed Care
Liver Impairment and Renal Impairment Related to COPD
06/19/2014
Tim Casey
San Diego—Patients with chronic obstructive pulmonary disease (COPD) who also had mild and moderate liver impairment or severe renal impairment tolerated a single orally-inhaled dose of olodaterol, according to 2 single-center, open-label...
San Diego—Patients with chronic obstructive pulmonary disease (COPD) who also had mild and moderate liver impairment or severe renal impairment tolerated a single orally-inhaled dose of olodaterol, according to 2 single-center, open-label...
San Diego—Patients with chronic...
06/19/2014
First Report Managed Care
Nintedanib Is Safe and Effective in Treating Idiopathic Pulmonary Fibrosis
06/19/2014
Tim Casey
San Diego—Patients with idiopathic pulmonary fibrosis (IPF) who received 150 mg of nintedanib twice daily had a significant reduction in the rate of decline of forced vital capacity (FVC) compared with a placebo group, according to 2 phase 3,...
San Diego—Patients with idiopathic pulmonary fibrosis (IPF) who received 150 mg of nintedanib twice daily had a significant reduction in the rate of decline of forced vital capacity (FVC) compared with a placebo group, according to 2 phase 3,...
San Diego—Patients with...
06/19/2014
First Report Managed Care
Interferon-Free Antiviral Regimen for Hepatitis C Patients without Cirrhosis
06/19/2014
Mary Mihalovic
A recent study has shown that an 8-week regimen consisting of the antiviral agents ledipasvir and sofosbuvir was just as effective as a 12-week regimen in previously untreated patients with hepatitis C without cirrhosis [N Engl J Med. DOI:...
A recent study has shown that an 8-week regimen consisting of the antiviral agents ledipasvir and sofosbuvir was just as effective as a 12-week regimen in previously untreated patients with hepatitis C without cirrhosis [N Engl J Med. DOI:...
A recent study has shown that an...
06/19/2014
First Report Managed Care
Combination Interferon-Free Treatment for Previously Treated and Untreated Patients with Hepatitis C and Cirrhosis
06/19/2014
Mary Mihalovic
Combination treatment of ritonavir-enhanced ABT-450 with ombitasvir, dasabuvir, and ribavirin was shown to be effective in both previously treated and untreated patients with hepatitis C and compensated cirrhosis, according to a recent study...
Combination treatment of ritonavir-enhanced ABT-450 with ombitasvir, dasabuvir, and ribavirin was shown to be effective in both previously treated and untreated patients with hepatitis C and compensated cirrhosis, according to a recent study...
Combination treatment of...
06/19/2014
First Report Managed Care
Previously Untreated Hepatitis C Patients Successfully Treated with Ledipasvir and Sofosbuvir
06/19/2014
Mary Mihalovic
A 12-week, single-tablet regimen consisting of the nucleotide polymerase inhibitor, sofosbuvir, and the NS5A inhibitor, ledipasvir, was shown to be highly effective in previously untreated patients with hepatitis C genotype 1, according to...
A 12-week, single-tablet regimen consisting of the nucleotide polymerase inhibitor, sofosbuvir, and the NS5A inhibitor, ledipasvir, was shown to be highly effective in previously untreated patients with hepatitis C genotype 1, according to...
A 12-week, single-tablet regimen...
06/19/2014
First Report Managed Care
Collagen Vascular Disease Is an Important Condition in Patients with IPF
06/19/2014
Kerri Fitzgerald
Commonly, interstitial pneumonia (IP) complicates collagen vascular disease (CVD) and IP may be the first or only manifestation of CVD. It is difficult to distinguish IP from CVD and many patients may be diagnosed with idiopathic IP....
Commonly, interstitial pneumonia (IP) complicates collagen vascular disease (CVD) and IP may be the first or only manifestation of CVD. It is difficult to distinguish IP from CVD and many patients may be diagnosed with idiopathic IP....
Commonly, interstitial pneumonia...
06/19/2014
First Report Managed Care
Study Finds Acetylcysteine Offers No Benefits for Patients with IPF
06/19/2014
Kerri Fitzgerald
Previous studies have suggested that acetylcysteine is a beneficial treatment for idiopathic pulmonary fibrosis (IPF); however, data from placebo-controlled trials are lacking. A recent study by the Idiopathic Pulmonary Fibrosis Clinical...
Previous studies have suggested that acetylcysteine is a beneficial treatment for idiopathic pulmonary fibrosis (IPF); however, data from placebo-controlled trials are lacking. A recent study by the Idiopathic Pulmonary Fibrosis Clinical...
Previous studies have suggested...
06/19/2014
First Report Managed Care
Pirfenidone Reduces Disease Progression in Patients with IPF
06/19/2014
Kerri Fitzgerald
Two previous phase 3 trials have found that pirfenidone reduced disease progression in patients with idiopathic pulmonary fibrosis (IPF), as measured by the decline in forced vital capacity (FVC) or vital capacity. However, another phase 3...
Two previous phase 3 trials have found that pirfenidone reduced disease progression in patients with idiopathic pulmonary fibrosis (IPF), as measured by the decline in forced vital capacity (FVC) or vital capacity. However, another phase 3...
Two previous phase 3 trials have...
06/19/2014
First Report Managed Care
COPD with GERD Associated with High Medicare Costs
06/19/2014
Kerri Fitzgerald
Chronic obstructive pulmonary disease (COPD) is associated with annual direct costs of $29.5 billion. COPD exacerbations are the key drivers of the healthcare costs, accounting for approximately 70%. Comorbid chronic conditions among COPD...
Chronic obstructive pulmonary disease (COPD) is associated with annual direct costs of $29.5 billion. COPD exacerbations are the key drivers of the healthcare costs, accounting for approximately 70%. Comorbid chronic conditions among COPD...
Chronic obstructive pulmonary...
06/19/2014
First Report Managed Care
The Future of Health Benefits for Retirees
06/19/2014
Melissa D. Cooper
There are an estimated 15 million Medicare beneficiaries using retiree health benefit plans as supplemental coverage. An additional >2 million pre-retirees are also using retiree health benefit plans as a primary source of coverage, making...
There are an estimated 15 million Medicare beneficiaries using retiree health benefit plans as supplemental coverage. An additional >2 million pre-retirees are also using retiree health benefit plans as a primary source of coverage, making...
There are an estimated 15...
06/19/2014
First Report Managed Care
Multiple Providers Prescribing Opioids in Medicare Patients
06/18/2014
Sarah O'Brien
The expansion of prescription opioids among adults >65 years of age may be an indication of a fragmented healthcare system, in which patients receive opioids from multiple physicians who do not or cannot communicate with one another,...
The expansion of prescription opioids among adults >65 years of age may be an indication of a fragmented healthcare system, in which patients receive opioids from multiple physicians who do not or cannot communicate with one another,...
The expansion of prescription...
06/18/2014
First Report Managed Care
Collaborative Care for Depression and Diabetes
06/18/2014
Kerri Fitzgerald
Studies have shown that diabetes is a chronic physical health condition often linked with symptoms of depression. Comorbid depression and diabetes can significantly worsen patient self-care, health, and economic burden of diabetes. The...
Studies have shown that diabetes is a chronic physical health condition often linked with symptoms of depression. Comorbid depression and diabetes can significantly worsen patient self-care, health, and economic burden of diabetes. The...
Studies have shown that diabetes...
06/18/2014
First Report Managed Care
Cost-Effectiveness of Aclidinium Bromide versus Tiotropium Bromide for COPD
06/18/2014
Mary Beth Nierengarten
The results of a model-based health economic study showed that the use of aclidinium bromide as maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) may be more cost-effective than tiotropium bromide...
The results of a model-based health economic study showed that the use of aclidinium bromide as maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) may be more cost-effective than tiotropium bromide...
The results of a model-based...
06/18/2014
First Report Managed Care
Patient Recall and Satisfaction of EHR Content
06/18/2014
Sarah O'Brien
Prior to electronic health records (EHRs), educational materials for patients were primarily handouts and pamphlets.
Prior to electronic health records (EHRs), educational materials for patients were primarily handouts and pamphlets.
Prior to electronic health...
06/18/2014
First Report Managed Care
Evolocumab Demonstrates Long-Term Efficacy for Hyperlipidemia
06/18/2014
Eileen Koutnik-Fotopoulos
Results from the DESCARTES (Durable Effect of PCSK9 Antibody Compared with Placebo Study) trial found that the investigational PCSK9 inhibitor, evolocumab, for the treatment of hyperlipidemia significantly reduced low-density lipoprotein...
Results from the DESCARTES (Durable Effect of PCSK9 Antibody Compared with Placebo Study) trial found that the investigational PCSK9 inhibitor, evolocumab, for the treatment of hyperlipidemia significantly reduced low-density lipoprotein...
Results from the DESCARTES...
06/18/2014
First Report Managed Care
Dapagliflozin Improves Glycemic Control without Weight Gain
06/18/2014
Kerri Fitzgerald
Diabetes medications are insulin-dependent, and the efficacy of these drugs diminishes when the function of pancreatic islet ß-cells declines during the progression of diabetes. Some diabetes drugs can cause weight gain in patients, which...
Diabetes medications are insulin-dependent, and the efficacy of these drugs diminishes when the function of pancreatic islet ß-cells declines during the progression of diabetes. Some diabetes drugs can cause weight gain in patients, which...
Diabetes medications are...
06/18/2014
First Report Managed Care
Managed Care Q&A
The Patient Protection and Affordable Care Act and Managed Care Repercussions - Q&A with Norm Smith, President of Viewpoint Consulting, Inc.
06/18/2014
First Report Managed Care conducted an interview with Norm Smith, one of our Editorial Advisory Board members, to discuss how the Patient Protection and Affordable Care Act (ACA) is impacting the managed markets, including costs, coverage,...
First Report Managed Care conducted an interview with Norm Smith, one of our Editorial Advisory Board members, to discuss how the Patient Protection and Affordable Care Act (ACA) is impacting the managed markets, including costs, coverage,...
First Report Managed Care...
06/18/2014
First Report Managed Care
Correlation between Health Literacy and Stroke Education Outcomes
06/18/2014
Eileen Koutnik-Fotopoulos
Inadequate health literacy is a pervasive problem with major implications for reduced health status and health disparities. Education is a fundamental strategy of stroke prevention and treatment, but the effect of health literacy on stroke...
Inadequate health literacy is a pervasive problem with major implications for reduced health status and health disparities. Education is a fundamental strategy of stroke prevention and treatment, but the effect of health literacy on stroke...
Inadequate health literacy is a...
06/18/2014
First Report Managed Care
IMS Health Identifies Potential $213.2 Billion Savings in Healthcare Costs
06/18/2014
Tim Casey
The IMS Health Institute for Healthcare Informatics issued a report saying the US healthcare system could save in annual healthcare costs if medications were used responsibly.
The IMS Health Institute for Healthcare Informatics issued a report saying the US healthcare system could save in annual healthcare costs if medications were used responsibly.
The IMS Health Institute for...
06/18/2014
First Report Managed Care
Conference Insider
The ACA and Changes in the Healthcare Industry
06/18/2014
Tim Casey
Orlando—By now, more than 4 years since the passage of the Patient Protection and Affordable Care Act (ACA), patients, providers, payers, and pharmaceutical companies have become accustomed to an evolving healthcare industry. Michael Lovdal,...
Orlando—By now, more than 4 years since the passage of the Patient Protection and Affordable Care Act (ACA), patients, providers, payers, and pharmaceutical companies have become accustomed to an evolving healthcare industry. Michael Lovdal,...
Orlando—By now, more than 4...
06/18/2014
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Trending Articles

Behind the Bill
CMS Updates Guidance on M3P: What to Expect from Medicare’s 2025 Rollout
07/24/2024
Katie Hayes, MJ
The M3P offers financial relief by spreading payment throughout the year, and CMS’ latest guidance clarifies key outreach parameters.
The M3P offers financial relief by spreading payment throughout the year, and CMS’ latest guidance clarifies key outreach parameters.
The M3P offers financial relief...
07/24/2024
First Report Managed Care
News
Dietary Patterns May Reshape Microbiota to Combat Obesity
08/19/2024
Lisa Kuhns, PhD, MD
Dietary patterns that promote beneficial gut microbiota show promise in combating obesity and related metabolic diseases, according to recent research published in Frontiers in Nutrition.
Dietary patterns that promote beneficial gut microbiota show promise in combating obesity and related metabolic diseases, according to recent research published in Frontiers in Nutrition.
Dietary patterns that promote...
08/19/2024
First Report Managed Care
News
High Mortality and Impairment Rates Among Older Adults in Long-Term Acute Care Hospitals
09/20/2024
Lisa Kuhns, PhD, MD
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals...
09/20/2024
First Report Managed Care
Conference Coverage
Assessing the Effectiveness of DTBZ in Promoting Psychiatric Stability in Patients With Tardive Dyskinesia
10/14/2024
Hannah Musick
Research presented at AMCP Nexus 2024 examines the impact of deutetrabenazine (DTBZ) on psychiatric stability in patients with tardive dyskinesia, showing a potential improvement in schizophrenia-related hospitalizations and emergency...
Research presented at AMCP Nexus 2024 examines the impact of deutetrabenazine (DTBZ) on psychiatric stability in patients with tardive dyskinesia, showing a potential improvement in schizophrenia-related hospitalizations and emergency...
Research presented at AMCP Nexus...
10/14/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Grace Taylor, MS, MA
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

June 2014 Volume 11 Issue 6

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use